Related references
Note: Only part of the references are listed.Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
V. Gregorc et al.
BRITISH JOURNAL OF CANCER (2009)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Justin Stebbing et al.
LUNG CANCER (2009)
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
Paolo A. Zucali et al.
CANCER (2008)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
David M. Jackman et al.
CANCER (2008)
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. K. Nowak et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041)
H. van Laarhoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
F. G. De Braud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
Jacek Jassem et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multidisciplinary treatment of malignant pleural mesothelioma
Giovanni Luca Ceresoli et al.
ONCOLOGIST (2007)
Impaired angiogenesis in aminopeptidase N-null mice
Roberto Rangel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
GR Oxnard et al.
LUNG CANCER (2006)
Variability in mesothelioma tumor response classification
SG Armato et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2006)
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha
A Sacchi et al.
CLINICAL CANCER RESEARCH (2006)
Medical progress - Advances in malignant mesothelioma
BWS Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
C Manegold et al.
ANNALS OF ONCOLOGY (2005)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne et al.
ANNALS OF ONCOLOGY (2004)
Molecular mechanisms of caspase regulation during apoptosis
SJ Riedl et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma
JG Edwards et al.
CHEST (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif
G Colombo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
